{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:39:39Z","timestamp":1779889179567,"version":"3.53.1"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PO1 HL68705"],"award-info":[{"award-number":["PO1 HL68705"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Light chain (<jats:styled-content style=\"fixed-case\">AL<\/jats:styled-content>) amyloidosis is a rare disease associated with significant, irreversible organ dysfunction and high case fatality. An observational study was conducted to assess health\u2010related quality of life (<jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL) in patients treated for <jats:styled-content style=\"fixed-case\">AL<\/jats:styled-content> amyloidosis between 1994 and 2014 with both high dose melphalan and stem cell transplantation (<jats:styled-content style=\"fixed-case\">HDM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) or non\u2010<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> chemotherapy regimens. The <jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\u201036v1<jats:sup>\u00ae<\/jats:sup> Health Survey (<jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\u201036) was administered to assess <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL during clinic visits. Analysis of variance was used to compare pre\u2010 and post\u2010treatment <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL within each treatment group to an age\u2010 and gender\u2010adjusted general population (<jats:styled-content style=\"fixed-case\">GP<\/jats:styled-content>) normative sample. Cox proportional hazard models were fit to examine associations between pre\u2010treatment levels of <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL and mortality within 1 and 5\u00a0years after initiating specific treatment regimens (<jats:styled-content style=\"fixed-case\">HDM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>:<jats:italic> n<\/jats:italic>\u00a0=\u00a0402; non\u2010<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> chemotherapy regimens: <jats:italic>n<\/jats:italic>\u00a0=\u00a0172). Among patients who received <jats:styled-content style=\"fixed-case\">HDM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>, there were significant improvements following treatment in vitality, social functioning, role\u2010emotional and mental health. Worse pre\u2010treatment <jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\u201036 physical component scores were associated with a greater risk of mortality in both treatment groups and follow\u2010up periods (<jats:italic>P\u00a0<\/jats:italic>\u2264<jats:italic>\u00a0<\/jats:italic>0\u00b7005 for both). [Correction added on 20 October 2017, after first online publication: This <jats:italic>P<\/jats:italic> value has been corrected]. Using <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL assessments in every physician visit or treatment may provide valuable insights for treating rare conditions like <jats:styled-content style=\"fixed-case\">AL<\/jats:styled-content> amyloidosis.<\/jats:p>","DOI":"10.1111\/bjh.14889","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T15:28:19Z","timestamp":1504020499000},"page":"461-470","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A longitudinal evaluation of health\u2010related quality of life in patients with <scp>AL<\/scp> amyloidosis: associations with health outcomes over time"],"prefix":"10.1111","volume":"179","author":[{"given":"Vaishali","family":"Sanchorawala","sequence":"first","affiliation":[{"name":"Amyloidosis Center Boston University School of Medicine Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1046","authenticated-orcid":false,"given":"Kristen L.","family":"McCausland","sequence":"additional","affiliation":[{"name":"Optum Johnston RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"White","sequence":"additional","affiliation":[{"name":"Optum Johnston RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha S.","family":"Bayliss","sequence":"additional","affiliation":[{"name":"Optum Johnston RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer D.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Prothena Biosciences, Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lo","sequence":"additional","affiliation":[{"name":"Amyloidosis Center Boston University School of Medicine Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Skinner","sequence":"additional","affiliation":[{"name":"Amyloidosis Center Boston University School of Medicine Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0564-2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1309-x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.100"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3350"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709253371306"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951509990216"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9510"},{"key":"e_1_2_8_9_1","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle R.A.","year":"1995","journal-title":"Seminars in Hematology"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.7.1817.1817"},{"key":"e_1_2_8_11_1","volume-title":"User's Manual for the SF\u201036v2 Health Survey","author":"Maruish M.E.","year":"2011"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2271"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095463"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12286"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2014.08.013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0089"},{"key":"e_1_2_8_17_1","volume-title":"How to Score Version 2 of the SF\u201036 Health Survey (standard and acute forms)","author":"Ware J.E.","year":"2000"},{"key":"e_1_2_8_18_1","volume-title":"SF\u201036 Health Survey: Manual & Interpretation Guide","author":"Ware J.E.","year":"2000"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24676"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:30:02Z","timestamp":1695961802000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/bjh.14889"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14889","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"assertion":[{"value":"2017-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}